ArticleBMC cancer2022
Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The impact of HPV/HIV co-infection on immunosuppression, HPV genotype, and cervical cancer biomarkers.BMC cancer · 2025Pooled it
- Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.International journal of cancer · 2026Article
- HPV integration as a triage tool for HPV-positive women in cervical cancer screening.Tumour virus research · 2026Article
- Risk of 3-Year Cytological Progression by Baseline HPV Status Among Women With Normal Cytology: A Multicenter Cohort Study.Cancer medicine · 2026Observational
- A multi-centre study on cervical cancer screening reveals population-related impact on cervical intraepithelial neoplasia rate.Frontiers in cellular and infection microbiology · 2026Article
- Association between multiple infection patterns of HPV33 and the risk of cervical carcinogenesis.Frontiers in microbiology · 2026Article
- HPV genotype-specific p16/Ki67 expression with machine learning-assisted assessment in cervical neoplasia.Frontiers in oncology · 2026Article
- Distribution of human papilloma virus genotypes in cancerous lesions of cervix: Insights from a hospital-based study in Bangladesh.Journal of education and health promotion · 2026Article
- Impact of Single- Versus Multiple-Type HPV Infections on Cervical Cytological and Histological Abnormalities: The Dominant Oncogenic Potential of HPV16 Single-Type Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Multiple high-risk human papillomavirus infections exacerbate cervical lesion risk: epidemiological evidence from suining, Sichuan.Virology journal · 2025Article
- High-risk human papillomavirus genotype distribution and attribution to cervical lesions in a Shanxi Province screening population.Scientific reports · 2025Article
- Significance of Genotype-Specific High-Risk Human Papillomavirus Testing in Cervical Cancer Screening: A Hospital-Based Study.Journal of medical virology · 2025Article
- High Prevalence of Human Papillomavirus in Vulvar Cancer Among Vietnamese Women: Implications for Vaccination Strategies.Cancer medicine · 2025Article
- The Prevalence of Multi-Type Infections Among Human Papillomavirus Types in Korean Women.Pathogens (Basel, Switzerland) · 2025Article
- Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.International journal of cancer · 2025Article
- Persistently high prevalence of HPV16 and rising prevalence of non-16/18 HR-HPV genotypes in cervical precancer and cancer in Latvia in 2016-2024 shape the severity of cervical disease.Frontiers in oncology · 2025Article
- The cervical cancer related distribution, coinfection and risk of 15 HPV types in Baoan, Shenzhen, in 2017-2023.Virology journal · 2024Article
- Nonlinear relationship between viral load and TCT in single/multiple HPV52 infection.Virology journal · 2024Article
- Clinical Validation of the Vitro HPV Screening Assay for Its Use in Primary Cervical Cancer Screening.Cancers · 2024Article
- The Future of Cervical Cancer Screening.International journal of women's health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study was to investigate the risk of human papillomavirus (HPV) genotyping particularly vaccine genotypes and multiple infections for cervical precancer and cancer, which might contribute to developing genotype-specific screening strategy and assessing potential effects of HPV vaccine.
methodsThe HPV genotypes were identified using the Seq HPV assay on self-collected samples. Hierarchical ranking of each genotype was performed according to positive predictive value (PPV) for cervical intraepithelial neoplasia 2/3 or worse (CIN2+/CIN3+). Multivariate logistic regression model was used to estimate the odds ratios (ORs) with 95% confidence interval (CI) of CIN2+ according to multiplicity of types and vaccine types.
resultsA total of 2811 HPV-positive women were analyzed. The five dominant HPV genotypes in high-grade lesions were 16/58/52/33/18. The overall ranking orders were HPV16/33/35/58/31/68/18/ 56/52/66/51/59/45/39 for CIN2+ and HPV16/33/31/58/45/66/52/18/35/56/51/68/59/39 for CIN3+. The risks of single infection versus co-infections with other types lower in the hierarchy having CIN2+ were not statistically significant for HPV16 (multiple infection vs. single infection: OR = 0.8, 95%CI = 0.6-1.1, P = 0.144) or other genotypes (P > 0.0036) after conservative Bonferroni correction. Whether HPV16 was present or not, the risks of single infection versus multiple infection with any number (2, ≥2, or ≥ 3) of types for CIN2+ were not significantly different. In addition, HPV31/33/45/52/58 covered by nonavalent vaccine added 27.5% of CIN2, 23.0% of CIN3, and 12.5% of cancer to the HPV16/18 genotyping. These genotype-groups were at significantly higher risks than genotypes not covered by nonavalent vaccine. Moreover, genotypes covered by nonavalent vaccine contributed to 85.2% of CIN2 lesions, 97.9% of CIN3 and 93.8% of cancers.
conclusionsPartial extended genotyping such as HPV33/31/58 but not multiplicity of HPV infections could serve as a promising triage for HPV-positive self-samples. Moreover, incidence rates of cervical cancer and precancer were substantial attributable to HPV genotypes covered by current nonavalent vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.